Haystack MRD® by Quest Diagnostics®

A New England Journal of Medicine study showed how ctDNA testing helped monitor treatment response in real time—without surgery, radiation, or chemo. Watch Dr. Andrea Cercek discuss the results 👉 hubs.la/Q041SHCK0 #CancerResearch #ctDNA #MRD #OncologyInnovation

Haystack MRD® is backed by the logistical and operational infrastructure of Quest Diagnostics®, delivering consistent, nationwide access to advanced testing. Learn more about Haystack MRD at hubs.la/Q041SJDn0 #ctDNA #MRD #oncology

100% of patients with #dMMR rectal cancer in a recent trial were successfully treated wtih #immunotherapy alone. Haystack MRD® was used to track treatment response through a minimally invasive #ctDNA blood test. Read more in the blog post: hubs.la/Q041SJmw0

Real-world case: Haystack MRD supported earlier treatment in an HR+ breast cancer patient where other MRD tests were negative. Learn more in our recently published case reports: hubs.la/Q041SGPl0 #Oncology #MRD #BreastCancer

In a real-world HR+ breast cancer case, Haystack MRD detected ctDNA missed by 2 other MRD assays—supporting earlier treatment and MRD clearance. Check out the full publication at hubs.la/Q041SJC20 #ctDNA #MRD #Oncology

Haystack MRD may uncover ctDNA at levels below what some other MRD assays report as their minimum detection range. Read published case reports to learn more: hubs.la/Q041SHPC0. #ctDNA #MRD

Don't miss our Industry Spotlight at SSO2026 on Haystack MRD® and confident care decisions in the surgical oncology setting. Thursday, March 5 at 3:35 PM in the HUB Theater. Learn more at hubs.la/Q0443XqT0 Hope to see you there! #PrecisionOncology #ctDNA #MRD

Ultradeep sequencing of 1M reads per molecule ensures each tracked variant is thoroughly interrogated. Haystack MRD combines this with patented error-correction technology that double-checks each variant for confident ctDNA results. Learn more at hubs.la/Q041SJBv0

Haystack MRD® brings confidence in #ctDNA results across surgical oncology settings. Meet the team at Quest Diagnostics booth 205 at #SSO2026 to learn more. hubs.la/Q0443Xl30 #Oncology #PrecisionOncology

Join us at #SSO2026 in Phoenix for a presentation on MRD-informed risk assessment across care settings. More details at hubs.la/Q0443Xny0 #ctDNA #MRD #PrecisionOncology

Missed the live webinar? Watch on demand as Time100 Health Honoree Dr. Andrea Cercek discusses how ctDNA testing with Haystack MRD guided immunotherapy-only treatment for dMMR cancers. 🎥 hubs.la/Q041SGDX0 #Oncology #ctDNA #Immunotherapy #MRD

Don't miss the presentation by Dr TJ Slavin, MD, MBA on assessing risk across neoadjuvant and postsurgical settings using Haystack MRD® at #SSO2026. Thursday, March 5 at 3:35 PM | HUB Theater Learn more at hubs.la/Q0443Y0G0 #ctDNA #MRD #Oncology #PrecisionOncology

Learn how Haystack MRD® was used to monitor treatment response in a groundbreaking immunotherapy study: hubs.la/Q041SGrV0 #CancerResearch #ctDNA #MRD #oncology

The Haystack MRD team will be at SSO 2026 on March 5-7 in Phoenix. Visit us at Quest Diagnostics booth 205 to learn how accurate minimal residual disease (#MRD) testing provides confident results to support decision-making across oncology settings hubs.la/Q0443W7Q0 #SSO2026

Patented error-correction technology double-checks each variant to help ensure MRD results reflect true biology, not noise. The result is exceptional accuracy for confident ctDNA results. Learn more at hubs.la/Q041SGM_0 #ctDNA #MRD #oncology

With technology originated by pioneers in cancer genomics at Johns Hopkins and further developed by Quest Diagnostics®, Haystack MRD® represents a legacy of innovation and deep oncology expertise. Learn more: hubs.la/Q041SGpX0 #CancerResearch #Oncology #PrecisionOncology

Haystack MRD® delivers clinically proven innovation, supported by technology featured or included in 2 NEJM-published studies. Read about the DYNAMIC study here: hubs.la/Q041SGX20 #PrecisionOncology #ctDNA #MRD #oncology

Haystack MRD® is backed by the logistical and operational infrastructure of Quest Diagnostics®, delivering consistent, nationwide access to advanced testing. Learn more about Haystack MRD at hubs.la/Q041SGpr0 #ctDNA #MRD #oncology

Ultradeep sequencing of 1M reads per molecule ensures each tracked variant is thoroughly interrogated. Haystack MRD combines this with patented error-correction technology that double-checks each variant for confident ctDNA results. Learn more at hubs.la/Q041SG6b0

Haystack MRD® is powered by Quest Diagnostics®, one of the world’s leading providers of diagnostic services. Quest provides a single-source solution with one of the broadest test portfolios in oncology and beyond. Learn more about Haystack MRD at hubs.la/Q041SDVG0